Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T13:39:55.818Z Has data issue: false hasContentIssue false

18 - The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers

Published online by Cambridge University Press:  19 January 2024

Daniel Gibbs
Affiliation:
Emeritus of Oregon Health and Science University
Get access

Summary

There has been growing evidence of the importance of inflammation in Alzheimer’s disease. Briefly, there have been a number of observations that people taking anti-inflammatory medications, particularly those with rheumatoid arthritis, may have a modestly reduced risk of getting Alzheimer’s disease. Studies in animal models have shown that brain inflammation has a dual response, protective in the acute reaction and detrimental when chronic. In these animal studies, chronic neuroinflammation activates inflammatory cells in the brain called microglia, increases beta-amyloid burden, and increases the production of hyperphosphorylated tau, the toxic form of tau protein found in neurofibrillary tangles. However, trials of anti-inflammatory medications such as ibuprofen in humans have for the most part failed to show a significant reduction in the risk of getting Alzheimer’s. Recent work has suggested that this damaging effect of inflammation on Alzheimer’s risk does indeed occur in humans but is specific to those carrying the APOE-4 allele.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kinney, JW, Bemiller, SM, Murtishaw, AS, Leisgang, AM, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement 2018; 4: 575590. https://doi.org/10.1016/j.trci.2018.06.014. PMID: 30406177; PMCID: PMC6214864 (open access).CrossRefGoogle ScholarPubMed
Tao, Q, Fang, Ang TFAA, Akhter-Khan, SC, et al. Impact of C-reactive protein on cognition and Alzheimer disease biomarkers in homozygous APOE ɛ4 carriers. Neurology 202197: e1243e1252. https://doi.org/10.1212/WNL.0000000000012512.CrossRefGoogle ScholarPubMed
Swanson, CJ, Zhang, Y, Dhadda, Set alA randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyAlz Res Therapy 2021; 13: 80. https://doi.org/10.1186/s13195-021-00813-8 (open access).CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×